{"nctId":"NCT03838874","briefTitle":"Mepivacaine Versus Low-Dose Bupivacaine For Primary Total Hip and Knee Arthroplasty","startDateStruct":{"date":"2019-02-25","type":"ACTUAL"},"conditions":["Knee Osteoarthritis","Hip Osteoarthritis"],"count":154,"armGroups":[{"label":"Low-Dose Bupivacaine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Low-Dose Bupivacaine"]},{"label":"Mepivacaine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Mepivacaine"]}],"interventions":[{"name":"Low-Dose Bupivacaine","otherNames":[]},{"name":"Mepivacaine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) physiological status I-III (patient must meet criteria of a status I-III in the ASA Physical Status Classification System: I=Normal Healthy Patient, II=Mild Systemic Disease, and III=Severe Systemic Disease)\n* Unilateral primary TKA or THA\n* 18+ years of age\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Chronic pain syndromes such as fibromyalgia or complex regional pain syndrome\n* Chronic opioid use (\\>1 mos) with OME \\>5 mg/day OR acute opioid use (\\< 1 mos) with OME \\> 30 mg/day.\n* Body mass index (BMI) \\> 45 kg/m2\n* Severe drug allergy\\* to medications used in this study, including non-steroidal anti-inflammatory drugs (i.e. celecoxib and ketorolac), and local anesthetics (defined as an immune reaction resulting in shortness of breath, hives, anaphylaxis, wheezing, and fever)\n* Major systemic medical comorbidities such as:\n\n  * Pre-existing severe renal disorder defined as glomerular filtration rate (GFR) \\<50 units/m2 (if labs are available), currently on dialysis, or highly suspected based on history.\n  * Severe hepatic disorder defined as current or past diagnosis of acute/subacute necrosis of liver, acute hepatic failure, chronic liver disease, cirrhosis (primary biliary cirrhosis), chronic hepatitis/toxic hepatitis, liver abscess, hepatic coma, hepatorenal syndrome, other disorders of liver\n* Contraindication to spinal anesthesia technique (e.g., known spinal stenosis, coagulopathy, sepsis, infection at site of injection, uncooperative, refusal, anticoagulation medications not held within appropriate time frame\\*). \\*Per ASRA guidelines, Clopidogrel (Plavix) held for at least 7 days, Dabigatran (Pradexa) held for at least 5 days, Rivaroxaban (Xarelto)held for at least 3 days, Warfarin (Coumadin)held for at least 5 days or recent INR of less than 1.4, Enoxaparin (Lovenox) with doses \\> 1 mg/kg held for close to 24 hours.\n* Known to be currently pregnant or actively breastfeeding. Patients that have a previous history of menopause, hysterectomy, or tubal ligation will not be required to perform a pregnancy test. Female patients that do not meet this criterion will be asked to submit a urine sample, and will require a negative urine sample in order to proceed with study protocol. Urine sample be collected pre-procedurally.\n* Impaired cognition","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Days","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Return of Lower Extremity Motor Function","description":"Assessed by measuring time from spinal anesthetic administration to postoperative achievement of Bromage 0 function (return of spontaneous ankle, knee, and hip movement) in the non-operative extremity at 15-minute intervals.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"210.3","spread":"79.54"},{"groupId":"OG001","value":"184.7","spread":"47.8"}]}]}]},{"type":"SECONDARY","title":"Post-Anesthesia Care Unit (PACU) Length of Stay","description":"Number of minutes subjects were admitted to PACU following the surgical procedure","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.2","spread":"33.6"},{"groupId":"OG001","value":"75.0","spread":"39.3"}]}]}]},{"type":"SECONDARY","title":"Hospital Length of Stay","description":"Number days subjects were admitted to the hospital following the surgical procedure","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"0.9"},{"groupId":"OG001","value":"1.4","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Maximum Pain Score","description":"Measured on a scale from 1 to 10 in the first 24 hours following the surgical procedure, 1=mild pain; 10=worst pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"2.5"},{"groupId":"OG001","value":"6.5","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Median Pain Score","description":"Measured on a scale from 1 to 10 in the first 24 hours following the surgical procedure, 1=mild pain; 10=worst pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"1.9"},{"groupId":"OG001","value":"3.4","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Discharge Pain Score","description":"Measured on a scale from 1 to 10 at time of hospital discharge, 1=mild pain; 10=worst pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"2.1"},{"groupId":"OG001","value":"3.5","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Orthostatic Hypotension","description":"Number of participants to experience orthostatic hypotension following the surgical procedure.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Urinary Retention","description":"Number of participants to experience urinary retention follow the surgical procedure.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Transient Neurologic Symptoms","description":"Number of participants to report transient neurologic symptoms","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":80},"commonTop":[]}}}